PeptideStack
5.2kquestions
20kanswers
220users

Is hair thinning on oral semaglutide dose-dependent or dose-rate dependent?

Asked 29 Apr 2026Modified 1 min agoViewed 3.8k times
5

Concretely: hair thinning · oral semaglutide.

I want to know whether this is a real physical effect or an artefact of how it is measured.

What prompted the question is an inconsistency between two sources I otherwise trust.

What is the causal chain, and where does it stop being established?

hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
shareeditfollowflag
MV
askedmala_venkatesh22k3729 Apr 2026
3Worth saying whether you are keeping fluids down, because that changes the answer. – e_dziedzic 4 months ago
2How severe, and does anything relieve it? Both matter for what people will say. – ilaria_bertone 3 months ago
add a comment

5 Answers

Accepted answer first, then by votes
39

Accepted answer

Answering this needs the rate of weight loss and the protein intake, since those are the two modifiable contributors.

The trigger in this context is the rate of weight loss and the associated nutritional deficit, not a pharmacological property. The same phenomenon is well documented after bariatric surgery, illness and childbirth.

Gastrointestinal adverse events, indicative pooled rates

EventActive armPlacebo armTiming
Nausea40–45 %15–20 %Peaks 1–2 wk after each step
Vomiting15–25 %5–8 %Follows nausea
Diarrhoea20–30 %10–15 %Early, variable
Constipation20–25 %8–12 %Later onset, persistent
Discontinuation for GI events4–7 %1–2 %Mostly during escalation

Ranges span agents and doses; read the specific prescribing information for a specific figure.

It is diffuse: increased shedding across the whole scalp, often noticed in the shower or on a brush, without a receding hairline or a defined crown pattern. Patterned loss is androgenetic and unrelated.

The two-to-four-month latency follows directly from the duration of the telogen phase and is the diagnostic feature of the condition.

Supplementing without a measured deficiency has no evidence behind it here and is not harmless at high doses.

The trigger is the rate of loss, not the compound. Slowing it helps future follicles.

shareimprove this answerflag
PM
answered · acceptedpieter_maas14k1720 Jun 2026
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
46

Answer first: the pattern reported here is telogen effluvium — a diffuse shed triggered by a physiological stressor — and rapid weight loss is a well-established trigger for it.

Adequate protein matters. Hair is largely keratin, and follicles are among the most metabolically active tissues, so they are early casualties of a substantial protein shortfall.

On the detail: in telogen effluvium a stressor shifts a large fraction of follicles from anagen into telogen simultaneously. Because telogen lasts around two to three months, the shed appears two to four months after the trigger rather than during it.

Research-use compounds are not approved for human use.

Diffuse and delayed means telogen effluvium. Patterned means something else.

edited 14 Aug 2026 by Dr_Nadia_Farsi — added the method parameters

shareimprove this answerflag
DF
answeredDr_Nadia_Farsi104k24716 Jul 2026
6Adding a vote because this deserves more of them. – j_wierzbicki 3 months ago
7Adding for future readers: fluids between meals rather than with them made a real difference. – ekaterina_volk 5 months ago
add a comment
30

The relevant biology is that a stressor pushes hair follicles synchronously from the growth phase into the resting phase, and the shed happens when they exit it.

Recovery follows the same timeline in reverse: shedding stops within a few months of the trigger resolving, and visible density returns over six to twelve months as regrowth reaches length.

Nothing topical has strong evidence for accelerating recovery from telogen effluvium specifically, as distinct from androgenetic loss where the evidence is entirely different.

Recovery of density over six to twelve months is the typical reported course where the trigger has resolved.

Protein intake is the modifiable nutritional factor worth attending to.

edited 1 Jul 2026 by v_ramaswamy — reworded for clarity after a comment

shareimprove this answerflag
VR
answeredv_ramaswamy68k5714 Jun 2026
I have seen this misattributed to the compound twice when it was the deficit. – bac_or_bust 1 months ago
add a comment
18

Iron, thyroid and vitamin D are the checks worth doing before concluding anything.

Slowing the rate of weight loss reduces the severity of the trigger. It does not reverse a shed already in progress, because the follicles have already committed.

Check ferritin, thyroid and vitamin D once, then stop investigating.

shareimprove this answerflag
DF
answeredDr_Nadia_Farsi104k24718 May 2026
4Worth flagging that this presents differently in people who titrated faster than the label. – s_kalniete 8 months ago
add a comment
15

Start with the timing, because telogen effluvium has a characteristic delay of two to four months between the trigger and the shed.

Worth checking: ferritin, thyroid function and vitamin D. Low ferritin in particular is associated with shedding at levels that are not low enough to cause anaemia.

Telogen effluvium following rapid weight loss is well documented in the dermatological literature, including extensive description after bariatric surgery.

It resolves in most cases over six to twelve months. That is genuinely the answer.

shareimprove this answerflag
CH
answeredcal_hennessy17k277 Jun 2026
7Same pattern here, and it resolved on the timeline described. – tare_and_weigh 6 months ago
6Small correction: the discontinuation rate in the trials is lower than most people assume. – Dr_Hanne_Solberg 5 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.